Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

American Journal of Hematology

Volumn 87, Issue 5, 2012, Pages 453-454

  Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; PARAPROTEIN; PLACEBO;

DISEASE COURSE; DRUG ACTIVITY; EDITORIAL; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CURCUMIN; FEMALE; HUMANS; MALE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA;

EID: 84859919751     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23204     Document Type: Editorial

References (22)

1. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 57-65.
2. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 180-186.
3. Gertz MA. Waldenstrom macroglobulinemia: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 2011; 86: 411-416.
4. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 2006; 354: 1362-1369.
5. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-569.
6. Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clinic proceedings Mayo Clinic 2010; 85: 945-948.
7. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375: 1721-1728.
8. Schuster S, Rajkumar SV, Dispenzieri A, et al. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol 2010; 85: 853-855.
9. Rajkumar SV. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res 2009; 15: 5606-5608.
10. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-2590.
11. Rajkumar SV. Treatment of multiple myeloma. Nature Rev Clin Oncol 2011; 8: 479-491.
12. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
13. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-5422.
14. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785-789.
15. Pérez-Persona E, Mateo G, García-Sanz R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2009; 148: 110-114.
16. Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. The New England journal of medicine 2011; 365: 474-475.
17. Golombick T, Diamond T, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) and curcumin: a randomised, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am J Hematol, in press.
18. Golombick T, Diamond TH, Badmaev V, et al. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res 2009; 15: 5917-5922.
19. Detweiler-Short K, Hayman S, Gertz MA, et al. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol 2010; 85: 737-740.
20. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 2005; 106: 812-817.
21. Mateos M-V, Lopez-Corral L, Hernandez M, et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on lenalidomide-dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with len alone vs no treatment. ASH Annual Meeting Abstracts 2011;118:991.
22. Anderson KC, Kyle RA, Rajkumar SV, et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2007; 22: 231-239.